The Goldman Sachs Group, Inc. 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-10 5:27 pm Sale |
2022-12-30 | 13G | Travere Therapeutics, Inc. TVTX |
GOLDMAN SACHS GROUP INC GS |
3,142,175 4.900% |
-1,457,104 (-31.68%) |
Filing |
| 2022-02-01 2:44 pm Purchase |
2021-12-31 | 13G | Travere Therapeutics, Inc. TVTX |
GOLDMAN SACHS GROUP INC GS |
4,599,279 7.500% |
4,599,279 (New Position) |
Filing |